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ABSTRACT 
Histone deacetylase inhibitors are members of a class of epigenetic drugs that 
have proven activity in T-cell malignancies, but little is known about their efficacy 
in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing 
histone deacetylase inhibitor that differs from approved inhibitors; its unique 
pharmacokinetic profile and oral dosing schedule, twice daily 4 hours apart, 
allows for continuous exposure at concentrations required for efficient tumor cell 
killing. In this phase 2 study, patients with relapsed/refractory non-Hodgkin 
lymphoma or chronic lymphocytic leukemia received oral abexinostat at 80 mg 
BID for 14 days of a 21-day cycle and continued until progressive disease or 
unacceptable toxicity. A total of 100 patients with B-cell malignancies and T-cell 
lymphomas were enrolled between Oct 2011 and Jul 2014. All patients received 
at least 1 dose of study drug; primary reasons for discontinuation included 
progressive disease (56%) and adverse events (25%). Grade ≥3 adverse events 
and any serious adverse events were reported in 88% and 73% of patients, 
respectively. The most frequently reported grade ≥3 treatment-emergent related 
adverse events were thrombocytopenia (80%), neutropenia (27%), and anemia 
(12%). Among the 87 patients evaluable for efficacy, overall response rate was 
28% (complete response, 5%), with highest responses observed in patients with 
follicular lymphoma (overall response rate, 56%), T-cell lymphoma (overall 
response rate, 40%), and diffuse large B-cell lymphoma (ORR, 31%). Further 
investigation of the safety and efficacy of abexinostat in follicular lymphoma, T-
 4 
cell lymphoma, and diffuse large B-cell lymphoma implementing a less dose-
intense week-on-week-off schedule is warranted. 
Trial registration identifier: EudraCT-2009-013691-47 
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Introduction 
Histone deacetylases (HDAC) and histone acetyl transferases control acetylation 
of histone and nonhistone proteins, thereby regulating gene transcription, protein 
function, and protein stability. The aberrant expression of HDAC proteins and 
mutation in the genes encoding HDACs have been linked to the development of 
cancers.1-3 The use of HDAC inhibitors causes hyperacetylation of histone and 
nonhistone proteins, leading to the transcriptional activation of tumor suppressor 
genes, as well as genes involved in cell cycle control, cell division, and 
apoptosis, resulting in antitumor activity.4 More recently, HDAC inhibitors have 
also been shown to exert immunostimulatory effects on cancer cells. Exposure to 
HDAC inhibitors was found to upregulate natural killer cell–activating ligands, 
major histocompatibility class I and II molecules, proteins involved in antigen 
presentation, and costimulatory molecules; in colon cancer cells, treatment with 
an HDAC inhibitor induced immunogenic cell death.5 In addition, HDAC inhibitors 
can block tumor angiogenesis and indirectly damage DNA by reducing RAD51 
protein and inhibiting DNA repair.4  
 
Currently, 4 HDAC inhibitors, vorinostat, romidepsin, belinostat, and panobinostat 
are approved for the treatment of cutaneous T-cell lymphoma, peripheral T-cell 
lymphoma, or multiple myeloma based on their potent and specific activity.6-10 
These agents, along with other HDAC inhibitors in development, are showing 
promising results in B-cell malignancies such as non-Hodgkin lymphoma (NHL) 
and chronic lymphocytic leukemia (CLL)11,12 and solid tumors such as breast 
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cancer.13 The tolerability profiles for different HDAC inhibitors vary. The most 
commonly reported adverse events include gastrointestinal effects (primarily 
diarrhea, nausea, and vomiting), constitutional effects (mainly fatigue), 
hematologic effects (thrombocytopenia and neutropenia), and cardiac toxicities 
(QTc prolongation); many of these toxicities were found to be dose-limiting.14  
 
Abexinostat, a novel, orally available hydroxamate-containing pan-HDAC 
inhibitor, differs from approved HDAC inhibitors due to its unique 
pharmacokinetic profile. Abexinostat was rapidly absorbed following oral 
administration, and a maximal plasma concentration was achieved within 0.5–1 
hour; the terminal elimination half-life was calculated to be approximately 4 
hours.15 Pharmacokinetic modeling was used to determine that the oral dosing 
schedule for abexinostat, twice daily 4 hours apart, allows for continuous 
exposure at concentrations required for efficient tumor cell killing while lowering 
the peak concentrations associated with once-daily oral administration.16 
Abexinostat may, therefore, offer a more active and potentially less toxic 
treatment option for cancer with a wider therapeutic index than other HDAC 
inhibitors in development.  
 
In a phase 1/2 study of 55 patients with relapsed or refractory lymphomas, 
abexinostat was administered on a 1-week-on/1-week-off schedule, and the 
recommended phase 2 dose was identified as 45 mg/m2 BID (equivalent to 80 
mg BID). At this dose, abexinostat was well-tolerated with significant clinical 
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activity and highly durable responses, especially in patients with multiply 
relapsed follicular lymphoma (FL).17 With this dosing schedule, the incidence of 
grade ≥3 thrombocytopenia was 20%. Another concurrent phase 1 study 
investigated other dosing schedules.15 During phase 1 of our study, the safety 
and efficacy of abexinostat using 3 different dosing schedules in 35 patients with 
relapsed or refractory NHL or CLL were evaluated.15 The recommended phase 2 
dose in this study was also 45 mg/m2 BID (equivalent to 80 mg BID) administered 
on a more dose-intense 2-weeks-on-1-week-off schedule. The use of abexinostat 
was associated with a manageable toxicity profile and durable responses with 
particular activity in patients with relapsed or refractory FL. Here, we report the 
safety and efficacy results of phase 2 of the same study. 
 
Methods  
This phase 2 study enrolled patients with relapsed/refractory NHL or CLL aged 
≥18 years with histologically confirmed NHL (including FL, T-cell lymphoma [T-
CL], diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], 
marginal zone lymphoma [MZL], or other subtypes) or immunophenotypically 
confirmed CLL. Patients with NHL other than T-CL had received ≥2 prior lines of 
standard therapy; patients with T-CL and CLL had received ≥1 prior treatment. 
Other eligibility criteria included estimated life expectancy >12 weeks, Eastern 
Cooperative Oncology Group performance status ≤2, adequate hematologic 
function (absolute neutrophil count >1 × 109/L, hemoglobin ≥8 g/dL, platelet 
count >100 × 109/L or 75 × 109/L in case of bone marrow involvement), adequate 
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renal function (creatinine <1.5 × upper limit of normal [ULN] or creatinine 
clearance ≥50 mL/min), adequate hepatic function (aspartate amino transferase 
and alanine aminotransferase <1.5 × ULN, total bilirubin <1.5 × ULN), and 
adequate cardiac functions with potassium levels within normal ranges with or 
without potassium correction. Exclusion criteria included allogeneic bone marrow 
transplant, major surgery within 4 weeks before the first abexinostat dose, 
corticosteroids within 10 days or valproic acid within 5 days before the first 
abexinostat dose, prior treatment with HDAC inhibitor other than valproic acid, 
concurrent therapeutic anticoagulation by antivitamin K, immunotherapy, 
chemotherapy (nitrosoureas within 6 weeks), and radiotherapy within 4 weeks 
before the first abexinostat dose.  
 
Written informed consent was obtained from all patients before enrollment. The 
Institutional Review Board, Research Ethics Board, and Independent Ethics 
Committee at each site reviewed and approved the protocol prior to initiation of 
the study. 
 
Patients were given oral abexinostat at 80 mg BID 4 hours apart for 14 days of a 
3-week cycle, and treatment was continued until progressive disease or 
unacceptable toxicity. The 80 mg BID dose, which corresponds to the 
recommended phase 2 dose of 45 mg/m2 BID, was identified in phase 1 of the 
study.15 For patients who could not tolerate abexinostat, treatment was 
discontinued until resolution of the adverse event; treatment was resumed at a 
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dose of 80 mg BID for 5 days per week for 2 weeks of a 3-week cycle in 
subsequent cycles. A further dose reduction to 60 mg BID for 5 days per week 
for 2 weeks of a 3-week cycle was also permitted, if necessary.  
 
The primary endpoint was overall response rate (ORR). Secondary endpoints 
included duration of response, progression-free survival (PFS), and overall 
survival. Patients were monitored for response at the end of every cycle. For 
patients with NHL, response was evaluated based on the recommendations of 
the International Working Group Revised Response Criteria for Malignant 
Lymphomas.18 Patients with CLL were evaluated for response according to the 
guidelines of the International Workshop on Chronic Lymphocytic Leukemia.19 
Adverse events were recorded at each visit using the National Cancer Institute 
CTCAE v3.0 criteria. 
 
This exploratory study enrolled approximately 16 patients per tumor type. For 
ORR, 95% exact (Clopper-Pearson) confidence intervals are provided. The 
Kaplan-Meier method was used for time-to-event analyses. 
 
Results 
Baseline Characteristics 
A total of 100 patients with NHL or CLL were enrolled in this phase 2 study 
between October 2011 and July 2014. Represented histologies included FL 
(n=18), DLBCL (n=17), MCL (n=16), T-CL (n=18), MZL and other subtypes 
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(n=15), and CLL/LL (n=16). Baseline characteristics are presented in Table 1. 
The median age of the population was 67 years (range, 32–85). The median 
number of prior therapies was 3 (range, 1–11). 
 
Treatment 
All patients received at least 1 dose of study drug. The median duration of 
treatment was 2.8 months (range, 0.7–35.4 months). Patients with FL continued 
abexinostat treatment longer than other NHL subtypes with a median treatment 
duration of 5.6 months. The most common primary reasons for withdrawal from 
the study were progressive disease (56%) and adverse events (25%). 
 
Safety 
Treatment-emergent adverse events related to study drug were reported in 98% 
of patients, with 82% experiencing grade ≥3 events. The most frequently 
reported grade ≥3 treatment-related AEs were thrombocytopenia (80%), 
neutropenia (27%), and anemia (12%). The incidence of any grade diarrhea was 
42%; however, only 3% of patients reported grade ≥3 diarrhea (Table 2).  
 
Serious AEs were reported in 73% of patients with 70% reporting grade ≥3 
serious AEs. The most commonly reported serious AEs included 
thrombocytopenia (54%), neutropenia (11%), anemia (7%), and pneumonia 
(6%). There were 5 deaths on study, although none of them were considered 
related to treatment by the investigators. 
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Because this trial was conducted at a fixed abexinostat dose, we analyzed 
whether patients with lower body surface area (BSA), who would have higher 
drug exposure, experienced greater toxicities. As expected, grade ≥3 AEs were 
more common in patients with a lower BSA than the median (1.8 m2) when 
compared with those with BSA at or above the median (98% vs. 78%). Serious 
AEs were also more common in patients with BSA lower than the median 
compared with those with BSA at or above the median BSA (90% vs. 56%). 
 
Adverse events led to dose reductions and treatment discontinuations in 21% 
and 29% of patients, respectively. Thrombocytopenia was the most common 
toxicity that caused dose reductions, occurring in 17% of patients. Other adverse 
events leading to dose reductions included asthenia (2 patients) and 
neutropenia, decreased appetite, hypernatremia, and decreased platelet 
aggregation (each in 1 patient). Treatment-emergent adverse events that led to 
treatment discontinuation in at least 2 patients included thrombocytopenia (12 
patients), neutropenia (3 patients), anemia (2 patients), and lung infection (2 
patients). Gastrointestinal toxicities resulted in no dose reductions and only 3 
discontinuations resulting from diarrhea, vomiting, and rectal hemorrhage in 1 
patient each (Supplementary Table 1).  
 
Across all tumor types, 4% of patients experienced cardiac treatment-emergent 
adverse events, with all events being reported as grade 1 or 2. One patient 
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experienced first-degree atrioventricular block and bradycardia; cardiac failure, 
defect in intraventricular conduction, and nodal arrhythmia were reported in 1 
patient each. None of these cardiac events were considered serious or related to 
treatment. Clinically significant abnormalities in electrocardiogram recordings 
were reported for 8 patients. T-wave inversion, atrial fibrillation, and isolated 
ventricular premature beat were each reported in 2 patients; localized ST 
depression and relevant QTc prolongations were each reported in 1 patient. 
 
In comparison to previous experience with abexinostat administered on a 1-
week-on/1-week-off schedule,17 weekly monitoring for thrombocytopenia showed 
that platelet counts fell sharply during the 14 days on abexinostat and recovered 
before the start of the next cycle as shown in Figure 1.  
 
Efficacy 
At a median follow-up of 18 months, 87 patients were evaluable for efficacy. The 
13 patients who did not have baseline or at least 1 post-baseline tumor 
evaluation were excluded from the efficacy analysis. The ORR across all tumor 
types was 28% (95% confidence interval [CI]: 19%–38%), with 5% of patients 
showing complete responses (CR) and a median duration of response of 8.8 
months (range, 0.0+–27.7+ months) as shown in Figure 2 and Table 3. Highest 
responses were observed in FL, T-CL, and DLBCL with ORRs of 56% (95% CI: 
30%−80%), 40%(95% CI: 16%−68%), and 31% (95% CI: 11%−59%). Median 
durations of response of 16.0 months (95% CI: 3.3−NA), 11.5 months (95% CI: 
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1.4−NA), and 1.9 months (95% CI: 0.7−13.6) were observed in each of these 
tumor types respectively. Among patients with T-CL, responses varied by 
subtypes with higher responses observed in patients with angioimmunoblastic T-
cell lymphoma (AITL) with an ORR of 71% (1 CR and 4 PRs in 7 evaluable 
patients) than in patients with peripheral T-cell lymphoma not otherwise 
characterized (ORR, 20%; 1 PR) and cutaneous T-cell lymphoma–mycosis 
fungoides/Sezary syndrome (ORR, 0%). The median PFS was 10.2 months 
(95% CI: 2.8 − NA) for FL, 5.5 months (95% CI: 2.8−NA) for T-CL, and 2.8 
months (95% CI: 1.4−3.7) for DLBCL (Figure 3). The PFS for all tumor 
histologies is shown in Supplementary Figure 1. Median overall survival was 
not reached for FL (95% CI: 18.4−NA), 17.8 months (95% CI: 11.2−NA) for T-CL, 
and 10.2 months (95% CI: 4.4−NA) for DLBCL (Figure 4). 
 
Discussion 
In this study, we report that the pan-HDAC inhibitor abexinostat showed an ORR 
across all tumor types of 28%. Promising response rates were observed in 
patients with FL, T-CL, and DLBCL with ORRs of 56%, 40%, and 31% in each of 
these NHL subtypes. Keeping in mind the difficulties involved in cross-trial 
comparisons, the results for abexinostat in FL are consistent with those of Evens 
et al, who reported an ORR of 64% with abexinostat in multiply relapsed 
disease.17 A median PFS of 10.2 months was observed for patients with FL in 
this study; a median PFS of 20.5 months was reported by Evens et al. 
Interestingly, oral vorinostat, which has been approved for cutaneous T-cell 
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lymphoma, yielded an ORR of 47% and a median PFS of 15.6 months when 
tested in patients with relapsed or refractory FL.20  
 
Among patients with DLBCL, the ORR of 31% obtained with abexinostat is 
similar to the ORR of 28% recently reported for oral panobinostat in relapsed 
DLBCL.21 In other B-cell malignancies, abexinostat was associated with a 
modest response rate (15%) among patients with MCL and MZL. No responses 
to abexinostat were observed among patients with relapsed/refractory CLL, a 
result that is consistent with reports from other trials of single-agent HDAC 
inhibitors in this tumor type.22-25 Response to abexinostat in T-CL varied by 
subtype, with the highest ORR (71%, including 14% CR) in AITL comparing 
favorably with the ORRs of 30% and 45% reported for romidepsin26 and 
belinostat.6 
 
Abexinostat showed a manageable toxicity profile in various NHL subtypes in this 
study. The most frequently occurring nonhematologic events were primarily 
gastrointestinal and included diarrhea (42%) and nausea (33%), with most of 
these events being grade 1 or 2 in severity. Although cardiac toxicities, especially 
QTc prolongations, are considered a dose-limiting class effect of HDAC 
inhibitors,14 the use of abexinostat was associated with a low incidence of cardiac 
events (3%), which resulted in only 1 patient discontinuing treatment. These 
toxicities and their rates of occurrence were comparable with those reported in 
the phase 1 study15 and substantially lower than the phase 1/2 study by Evens et 
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al, which reported incidences of nausea and diarrhea of 63% and 50%, 
respectively, although most of these events were low grade.17 Hematologic 
adverse events in this study, however, were more frequent and generally more 
severe than those reported by Evens et al. The incidence of grade ≥3 
hematologic adverse events in this study compared to the Evens study were 
thrombocytopenia (80% vs 20%) and neutropenia (27% vs 13%).17  
 
The difference in the toxicity profiles of abexinostat between the 2 studies may 
largely be attributed to the differences in dosing schedules used. Abexinostat, 
when administered on a 2-weeks-on/1-week-off schedule, is associated with 
higher rates of grade ≥3 hematologic events. In contrast, the 1-week-on/1-week-
off schedule was associated with lower rates of high-grade hematologic toxicities. 
As shown in Figure 1, the platelet counts fell sharply during the 14 days of 
abexinostat and recovered during the week patients were off treatment. In 
contrast, fluctuations in platelet counts were less sharp and less prominent with 
the 1-week-on/1-week-off schedule. Given that hematologic toxicities, especially 
thrombocytopenia, were dose-limiting in our study, the 1-week-on/1-week-off 
dosing schedule will be explored in future studies.  
 
In conclusion, this phase 2 study showed that abexinostat is clinically active in 
patients with relapsed/refractory NHL, especially in patients with FL, T-CL, and 
DLBCL, who exhibited high response rates and durable tumor control. 
Abexinostat showed good tolerability during prolonged drug administration; 
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however, using a less dose-intense schedule may mitigate the hematologic 
toxicity. Abexinostat is currently being tested in a variety of clinical trial settings, 
and further examination in FL, T-CL, and DLBCL is warranted. 
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Table 1. Baseline characteristics 
Characteristic 
FL 
(n=18) 
DLBCL 
(n=17) 
MCL 
(n=16) 
T-CL* 
(n=18) 
MZL/ 
Other 
(n=15) 
CLL/ LL 
(n=16) 
All  
(N=100) 
Age, years 
    Median (range)  
60  
(32–83) 
63  
(38–85) 
69  
(59–82) 
61  
(47–78) 
69  
(52–78) 
71  
(46–80) 
67  
(32–85) 
Gender, n (%)  
    Female 
 
9 (50) 
   
10 (59) 
 
6 (38) 
 
9 (50) 
 
4 (27) 
 
7 (44) 
 
45 (45) 
Median BSA, m2 
(range) 
1.9  
(1.3–2.3) 
1.7  
(1.4–2.4) 
1.7  
(1.4–2.1) 
1.8  
(1.5-2.1) 
1.8  
(1.5–2.1) 
1.9  
(1.4–2.1) 
1.8  
(1.3–2.4) 
Baseline ECOG performance status, n (%) 
    0 10 (56) 5 (29) 7 (44) 9 (50) 6 (40) 9 (56) 46 (46) 
    1 8 (44) 11 (65) 9 (56) 9 (50) 9 (60) 7 (44) 53 (53) 
    2 0 (0) 1 (6) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
Ann Arbor stage, n (%) 
I 1 (6) 1 (6) 2 (13) 0 (0) 0 (0)† NA 4 (4) 
II 8 (44) 5 (29) 1 (6) 1 (6) 1 (7)† NA 16 (16) 
III 2 (11) 5 (29) 1 (6) 4 (22) 4 (27)† NA 16 (16) 
IV 7 (39) 6 (35) 12 (75) 13 (72) 5 (33)† NA 43 (43) 
Prior treatments 
Median (range) 4.5 
(1–11) 
3 
(1–10) 
3 
(1–8) 
2 
(1–5) 
4 
(1–7) 
2.5 
(1–6) 
3 
(1–11) 
Radiotherapy, n 
(%) 
4 (22) 8 (47) 5 (31)  3 (17) 2 (13) 0 (0) 22 (22) 
Median time from 
diagnosis, months 
(range) 
59.5  
(16–156) 
18  
(5–121) 
38 
(13–108) 
23 
(3–99) 
90 
(18–252) 
69 
(19–113) 
47 
(3–252) 
Abbreviations: BSA, body surface area; CLL, chronic lymphocytic leukemia; DLBCL, 
diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FL, 
follicular lymphoma; LL, lymphoblastic lymphoma; MCL, mantle cell lymphoma; MZL, 
marginal zone lymphoma; T-CL, T-cell lymphoma. 
*Of 18 patients with T-CL treated, 8 presented with angioimmunoblastic T-cell 
lymphoma, 6 with peripheral T-cell lymphoma not otherwise characterized, and 4 
with cutaneous T-cell lymphoma–mycosis fungoides/Sezary syndrome. 
†Data not available for 5 patients  
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Table 2. Treatment-related adverse events by grade occurring in ≥5% of patients 
 
Adverse Event, % Any Grade Grades 3/4 
Any related adverse event 98 82 
Hematologic 
toxicities 
Thrombocytopenia 87 80 
Neutropenia 34 27 
Anemia 20 12 
Nonhematologic 
toxicities 
Diarrhea 42 3 
Nausea 33 2 
Asthenia 27 5 
Decreased appetite 23 0 
Vomiting 17 0 
Fatigue 11 0 
Epistaxis 7 0 
Muscle spasms 6 0 
Weight decreased 5 0 
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Table 3. Overall response and median duration of response among responders 
by tumor type 
 
Tumor type 
Number of 
Evaluable 
Patients 
ORR, % 
(CR, %) 
 
ORR 
95% CI 
Median DOR, 
months (range) 
 
Median 
DOR 
95% CI 
FL 16 56 (6) 30–80 16.0 (0.0+–27.7+) 3.3−NA 
DLBCL 16 31 (6) 11-59 1.9 (0.7–13.6) 0.7−13.6 
MCL 13 15 (8) 2–45 3.6 (2.8–4.3) 2.8−4.3 
T-CL 15 40 (7) 16–68 11.5 (1.4–11.8+) 1.4−NA 
MZL/Other 13 15 (0) 2–45 8.9 (8.8–9.0) 8.8−9.0 
CLL/LL  14 0 (0) 0–23 NA 16.0−NA 
Overall 87 28 (5) 19–38 8.8 (0.0+–27.7+) 3.3−13.6 
Abbreviations: CLL, chronic lymphocytic leukemia; CI, confidence intervals; CR, 
complete response; DLBCL, diffuse large B-cell lymphoma; DOR, duration of 
response; FL, follicular lymphoma; LL, lymphoblastic lymphoma; MCL, mantle cell 
lymphoma; MZL, marginal zone lymphoma; NA, not available; ORR, overall 
response rate; T-CL, T-cell lymphoma. 
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Figure Legends 
 
Figure 1. Thrombocytopenia with abexinostat treatment. A. Platelet counts and 
B. incidence of grade ≥3 thromoboctyopenia. 
 
Figure 2. Change in lymph node size. Waterfall plot of maximum change from 
baseline of the sum of products of the greatest diameters during the treatment 
phase. 
 
Figure 3. Progression-free survival in FL, DLBCL, and T-CL. 
 
Figure 4. Overall survival in FL, DLBCL, and T-CL.  
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Supplementary Table 1. Gastrointestinal and hematologic toxicities leading to 
dose reductions and treatment discontinuations 
 
 Gastrointestinal Toxicities Hematologic Toxicities 
Diarrhea Nausea Vomiting Thrombo-
cytopenia 
Neutropenia Anemia 
Incidence of 
any related 
grade (grade 
3/4) events, % 
42 (3) 33 (2) 17 (0) 87 (80) 34 (27) 20 (12) 
Led to dose 
reduction, % 
0 0 0 17 1 0 
Led to 
treatment 
discontinuation,
 % 
1 0 1 12 3 2 
Median time to 
onset of first 
event, days 
(range) 
8 
(1–233) 
6 
(1–130) 
7.5 
(1–233) 
14 
(4–100) 
36 
(4–288) 
32.5 
(1–511) 
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Supplementary Figure 1: Progression-free survival in different tumor types 
 
 
 
Abbreviations: CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell 
lymphoma; FL, follicular lymphoma; LL, lymphoblastic lymphoma; MCL, mantle cell 
lymphoma; MZL, marginal zone lymphoma; PFS, progression-free survival; T-CL, T-
cell lymphoma. 
 		
